MET and gastric cancer: This patient was enrolled on to a MET inhibitor (small molecule) trial, and as implicated in genomic alterations, his stomach cancer was responsive to the MET inhibitor, but his peritoneal seeding was rapidly deteriorating, which resulted in death from the disease.